FDA approves new drug for deadly lung cancer
The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer.
May 17, 2024
0
42
Pathological Conditions, Signs and Symptoms: News and Research on Cytokine Release Syndrome
MeSH tree: C23.550.470.790.250
Tumor tissue on a chip: New possibilities for cell therapies and personalized medicine
How do tumors react to a certain therapeutic approach? Knowing this before the start of a therapy would be of enormous value for people suffering from cancer as well as for the doctors treating them.
May 15, 2024
0
45
CAR T cell therapy targeting HER2 antigen shows promise against advanced sarcoma in clinical trial
Researchers at Texas Children's Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and Houston Methodist have published results of a Phase I clinical trial of a ...
Apr 24, 2024
0
54
FDA approves Abecma for relapsed, refractory multiple myeloma
The U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.
Apr 10, 2024
0
35
COVID-19 research: Study reveals new details about potentially deadly inflammation
A recent USC study provides new information about why SARS-CoV-2, the virus behind the COVID-19 pandemic, may elicit mild symptoms at first but then, for a subset of patients, turn potentially fatal a week or so after infection. ...
Mar 29, 2024
0
150
New research results explore the safety of short-term cultivated CAR T cells in cancer immunotherapy
Chimeric antigen receptor T cells—CAR T cells for short—are immune cells (T cells) that are taken from the body and genetically modified outside the body in the laboratory using transport vehicles for the genes to be transmitted ...
Mar 22, 2024
0
32
'Switchable' bispecific antibodies pave way for safer cancer treatment
In the ever-evolving battle against cancer, immunotherapy presents a turning point. It began with harnessing the body's immune system to fight cancer, a concept rooted more than a century ago but only gaining significant ...
Feb 21, 2024
0
63
CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies
Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived ...
Jan 18, 2024
0
77
Minimizing immunotherapy's potentially harmful side effects
Recent advances in treating multiple myeloma, the second most common blood cancer, and other blood malignancies are providing improved outcomes—and hope—to patients worldwide.
Jan 4, 2024
0
43
Third-generation anti-CD19 CAR T-cells show efficacy without neurotoxicity in B-cell lymphoma phase 1 clinical trial
The Malaghan Institute of Medical Research, in collaboration with Wellington Zhaotai Therapies Limited, today announced results of its phase 1 dose escalation trial of a new third generation anti-CD19 chimeric antigen receptor ...
Dec 11, 2023
0
51
